Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heartfailure-related health status (KCCQ) in cardiometabolic HFpEF – – Findings support further ...

Entrada Therapeutics has secured authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and ...

Lord James O’Shaughnessy has welcomed the UK government’s official response ... with a 48% reduction in participation in phase 3 trials that provide the NHS with the highest income.

UK biotech KaNDy Therapeutics is heading to phase 3 with its non-hormonal menopause drug, after a mid-stage trial showed it reduced hot flashes as well as improved quality of life, setting up a ...

One of the world’s leading phase I trial centres in oncology ... Therapy Group within the Centre for Cancer Drug Discovery (formerly called Cancer Research UK Cancer Therapeutics Unit) at the ICR, ...

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Praxis Precision Medicines has been blindsided by a recommendation to stop a phase 3 essential tremor trial. Two months after CEO Marcio Souza said the chances of the trial being futile were ...